You are here

fezolinetant

Astellas builds case for menopause drug fezolinetant

Pharmaphorum

Thu, 11/30/23 - 09:54 am

Astellas reports data from Phase IIIb trial to treat VMS due to menopause

Clinical Trials Arena

Wed, 06/28/23 - 09:58 am

clinical trials

Astellas' Menopause Drug Scores FDA Approval, After Regulatory Setback

Yahoo/Benzinga

Mon, 05/15/23 - 11:21 am

Astellas has menopause accelerated approval ambition thwarted by FDA at last minute

Fierce Biotech

Mon, 02/20/23 - 12:19 pm

Astellas buys Super Bowl commercial spot to raise menopause awareness

Medical Marketing and Media

Sun, 02/12/23 - 07:36 pm

DTC advertising

What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision

Endpoints

Wed, 11/2/22 - 11:00 pm

patient education

Astellas reports Phase III data of fezolinetant for menopause-linked VMS

Clinical Trials Arena

Tue, 09/6/22 - 10:50 am

clinical trials

vasomotor symptoms

Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record

Fierce Biotech

Thu, 08/18/22 - 12:40 pm

clinical trials

Astellas' menopause drug suffers rare setback as failed Asian trial blots previously pristine record

Fierce Biotech

Tue, 03/15/22 - 10:41 am

clinical trials

Astellas’ eyes filings for menopause drug fezolinetant after ph3 win

Pharmaforum

Mon, 03/7/22 - 10:07 am

clinical trials

Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Endpoints

Fri, 02/19/21 - 10:27 am

clinical trials

Astellas pushes non-hormonal menopause drug into phase 3

Pharmaforum

Wed, 08/7/19 - 11:48 pm

clinical trials